Serum 25-hydroxyvitamin D level and risk of benign prostatic hyperplasia: a prospective cohort study of 195,074 males
Journal of Men s Health · 05.06.2026
DOI: 10.22514/jomh.2026.044 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Men s Health, online erschienen am 05.06.2026. Verfasst von Youmin Yang und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Benign prostatic hyperplasia (BPH) gives rise to benign prostatic enlargement owing to unregulated hyperplasia of the epithelial and fibromuscular components within the transition zone and periurethral area. Vitamin D is a pleiotropic steroid hormone with functions that encompass the modulation of calcium and phosphate metabolism and the preservation of skeletal health, but prospective evidence in BPH is unclear.
Methods
We analyzed data from 195,074 participants in the UK Biobank (recruited 2006–2010) with valid vitamin D measurements and without prevalent BPH. Serum vitamin D was measured using the chemiluminescent immunoassay approach (units: nmol/L). Incident BPH cases were identified through linkage to hospital, primary care, and death registry records until 2022. We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Vitamin D was modeled as both a continuous variable and in quartiles. Dose-response relationships were examined using restricted cubic splines, with thresholds determined by maximally selected rank statistics. Subgroup and sensitivity analyses assessed robustness.
Results
Over a median follow-up of 13.3 years, 21,168 incident BPH cases were documented. Lower serum vitamin D was associated with an increased risk of BPH. Multivariable-adjusted HRs (95% CIs) were calculated for participants grouped by serum 25-hydroxyvitamin D (25(OH)D) quartiles, yielding values of 1.00 (reference), 0.95 (0.91, 0.99), 0.94 (0.90, 0.98), and 0.95 (0.91, 0.98) for the first to fourth quartiles, respectively. Each 1-standard deviation (SD = 20.9) increase corresponded to a 2% lower risk (HR = 0.98, 95% CI: 0.97–0.99). Restricted cubic spline analysis revealed a progressive decrease in risk with evidence of nonlinearity, which may exist due to saturation effect.
Conclusions
Based on large-scale prospective cohort data from the UK Biobank, this study validates that serum 25(OH)D levels are inversely associated with BPH risk.
Zitieren
APA
Yang, Y., Cheng, C., Xiong, Y., Qin, F., Yuan, J., Zhang, F., & Wang, X. (2026). Serum 25-hydroxyvitamin D level and risk of benign prostatic hyperplasia: a prospective cohort study of 195,074 males. Journal of Men s Health. https://doi.org/10.22514/jomh.2026.044
Vancouver
Yang Y, Cheng C, Xiong Y, Qin F, Yuan J, Zhang F, et al. Serum 25-hydroxyvitamin D level and risk of benign prostatic hyperplasia: a prospective cohort study of 195,074 males. Journal of Men s Health. 2026. doi:10.22514/jomh.2026.044
BibTeX
@article{Yang2026,
author = {Yang, Youmin and Cheng, Chao and Xiong, Yang and Qin, Feng and Yuan, Jiuhong and Zhang, Fuxun and Wang, Xianding},
title = {Serum 25-hydroxyvitamin D level and risk of benign prostatic hyperplasia: a prospective cohort study of 195,074 males},
journal = {Journal of Men s Health},
year = {2026},
doi = {10.22514/jomh.2026.044}
}
EUVIMED